L’Oréal has signed license agreement with Micreos, a Dutch comapny that is a leader in targeted bacterial biotechnology. The company markets Gladskin, shown above.  

L’Oréal and Micreos will join their expertise in biotechnology and the skin microbiome, the community of bacteria and microorganisms that live on the skin. Micreos will give L’Oréal access to its endolysin, a type of active protein in the cosmetic field. With this technology, it is possible for the first time to target only unwanted bacteria in the skin flora – responsible for many skin problems – while sparing the good ones.

For 15 years, L’Oréal’s Research & Innovation has been cooperating with scientific institutions and conducting clinical studies to better understand the role of the skin microbiome. “The agreement with Micreos opens up a very promising field in high-tech cosmetics,” says Laurent Attal, Executive Vice-President Research & Innovation of L’Oréal.

Micreos CEO Mark Offerhaus comments, “We expect this partnership to be ground-breaking. L’Oréal has been a leader in skincare for decades. Micreos is at the forefront of targeted bacterial biotechnology. We pair our strengths and millions stand to benefit.”

Micreos’ pharma development program includes endolysins that all target Staphylococcus bacteria, which cause or aggravate a broad range of health issues, including skin conditions.

Micreos has developed first-in-class proprietary products and technology, including their products which are currently on the market under the brandname Gladskin.